Skin Cancer News & Features

Erivedge Approved to Treat Basal Cell Carinoma

January 31, 2012

Erivedge (vismodegib) has been approved by the U.S. Food and Drug Administration to treat the most common form of skin cancer, basal cell carcinoma, the agency said Monday.
 

ACS annual report says cancer mortality is decreasing

Delicia Honen Yard January 10, 2012

Cancer incidence rates in men declined by 0.6% per year and remained stable in women and cancer mortality fell by 1.8% per year for men and by 1.6% per year for women between 2004 and 2008.
 

Cutaneous melanoma begets cutaneous melanoma

Delicia Honen Yard January 06, 2012

Continued skin surveillance is important for survivors of cutaneous melanoma (CM), indicate findings showing that this is the most common second primary cancer among persons with a first CM.
 

Gene sequencing can match patients to best cancer trials

Delicia Honen Yard December 15, 2011

Identifying the "mutational landscape" of a person's cancer is a promising method of determining which trials are best-suited to the patient's particular case.
 

Laser therapy may be an option in removal of premalignant skin lesions

Delicia Honen Yard December 07, 2011

When surgery or radiation therapy cannot be used to remove the common precancerous skin lesion lentigo maligna, carbon dioxide laser ablation may be a useful alternative.
 

New treatments are improving outcomes in melanoma

John Schieszer October 19, 2011

Targeted therapy, combination therapies, vaccines, and new treatment modalities demonstrate promising prognoses for these patients.
 

Arthritis drugs may raise risk of skin cancer

Delicia Honen Yard September 30, 2011

Tumor necrosis factor (TNF) inhibitors—biologic agents used in the treatment of rheumatoid arthritis—appear to increase the risk of skin cancer, including melanoma.
 

Frailty undermines outcomes in melanoma

Delicia Honen Yard September 14, 2011

In persons with stage III melanoma, frailty—not age—was associated with decreased disease-free survival and distant disease-free survival, and with more surgical complications.
 

Caffeine: The new sunblock?

Delicia Honen Yard September 02, 2011

Applying caffeine directly to the skin may eventually prove to help prevent sunlight-induced skin cancer, suggest the findings from a recent mouse study.
 

Ipilimumab (Yervoy)

August 01, 2011

Ipilimumab is a recombinant, human cytotoxic T-lymphocyte antigen 4-blocking monoclonal antibody indicated for the treatment of unresectable or metastatic melanoma.
 

Skin Cancer Clinical Trials

Clinical Trial: Dasatinib in Treating Patients With Unresectable or Metastatic Squamous Cell Skin Cancer or RAI Stage 0-I Chronic Lymphocytic Leukemia

Clinical Trial: Studying a Tumor Marker for Testicular Cancer, Skin Cancer, Small Intestine Cancer, and Pancreatic Cancer

Clinical Trial: Correlation Between Skin Carotenoid Levels and Previous History of Skin Cancer

Clinical Trial: Skin Cancer Prevention (VAKCCT)

Clinical Trial: CERTICOEUR: A Secondary Prevention Study of Skin Cancers in Heart Transplant Patients. Everolimus Versus Calcineurin Inhibitors Multicenter Trial

Free CE from mycme.com

Discussions on Emerging Concepts and Controversies in the Treatment of Patients with Advanced Non-Small Cell Lung Cancer

2.00 / AMA PRA Category 1 Credit(s)TM
This program reviews developments in maintenance therapy and evaluates the relevance of tumor histology and biomarker analysis for the management of NSCLC patients.
 

Cancer care is expensive.
CancerCare can help.


Connect Booklets
 Subscribe to the RSS for this page  [view all our RSS feeds here]

Web Exclusives

Psychosocial approach useful in managing cancer pain

February 03, 2012

Psychosocial interventions, including skills instruction and education, can help reduce pain in persons with cancer, confirm the results of a recent meta-analysis.
 

Experimental agent slows progression of colorectal cancer

February 02, 2012

The investigational drug regorafenib conferred a statistically significant survival benefit in patients with metastatic colorectal cancer in whom no standard therapy was effective.
 

In HER2 breast cancer, lapatinib works better with trastuzumab than without

February 01, 2012

Lapatinib is not as effective as trastuzumab against (HER2)-positive breast cancer, but combining the two nearly doubles the effectiveness seen with either one alone.
 

This material may not be published, broadcast, rewritten or redistributed in any form without prior authorization.

Your use of this website constitutes acceptance of Haymarket Media's Privacy Policy and Terms & Conditions